[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Biological Dynamics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100487318","exoluminate-study-for-early-detection-of-pancreatic-cancer-100487318",false,"NCT05625529","ExoLuminate Study for Early Detection of Pancreatic Cancer","Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients","Inclusion Criteria:\n\n* ≥18 years old.\n* Meeting criteria for one of the study cohorts.\n* Capable of giving informed consent.\n* Able to provide a blood sample.\n\nExclusion Criteria:\n\n* \\\u003C 18 years old.\n* Pregnancy.\n* Active cancer (other than pancreatic cancer) and\u002For undergoing treatment for an active cancer diagnosis (except for skin malignancies).\n* Prior organ transplant or bone marrow transplant.\n* History of fainting or other adverse effects when blood is drawn.\n* Any condition that, in the opinion of the investigator, should preclude enrollment.","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","3 Years","OBSERVATIONAL","ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC).\n\nThose with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis.\n\nThe goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.",[25,26,27,28],"Pancreas Cancer","Exosomes","Extracellular Vesicles","Pancreatic Neoplasms",[30,26,27,31,32,33],"Early Detection","IPMN","PDAC","Pancreatic Cancer","RECRUITING","2025-07-24",{"date":37,"type":38},"2025-07-28","ACTUAL",{"date":40,"type":38},"2022-12-19",{"date":42,"type":20},"2028-01-01",{"name":44,"class":45},"Biological Dynamics","INDUSTRY",""]